<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01940731</url>
  </required_header>
  <id_info>
    <org_study_id>CCTQ01458-2-CTF</org_study_id>
    <nct_id>NCT01940731</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Colistimethate Sodium Injection Vial to Treat Hospital-acquired Pneumonia in Adults</brief_title>
  <official_title>A Prospective, Open, Non-controlled, Multi-center Study of Efficacy and Safety of Colistimethate Sodium Injection Vial to Treat Hospital-acquired Pneumonia in Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To evaluate the clinical and microbiological efficacy and safety of Colistimethate
           sodium Injection Vial to treat adults with hospital-acquired pneumonia .

        2. To Learn the pharmacokinetic characteristics of continuous intravenous infusion of
           Colistimethate sodium.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Per subject clinical cure rate</measure>
    <time_frame>14-28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Per subject microbiological cure rate</measure>
    <time_frame>14-28 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hospital-acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Colistimethate sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colistimethate sodium</intervention_name>
    <description>3-5mg/(kg.d)(if CLcr≥80 mL/min),The maximum dose≤300mg/d 2.5-3.8mg/(kg.d)（if CLcr=50-79mL/min），The maximum dose≤230mg/d twice a day</description>
    <arm_group_label>Colistimethate sodium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged between 18-75, either male or female

          2. Women of childbearing age having negative pregnancy test at the time of enrollment and
             agreeing to take effective contraceptive measures from the delivery to 7 ~14 days
             after stopping .

          3. Defined as hospital-acquired pneumonia with following criteria

          4. fever, axillary temperature ≥37.3℃, oral temperature≥37.8℃, tympanic
             temperature≥38.2℃, rectal temperature≥38.4℃ or hypothermia rectal temperature&lt;35℃

          5. WBC&gt;10000/μL or &lt;4000μL, neutrophils&gt;70%, rod neutrophils&gt;10%

          6. Pathogens are or highly suspected to be aerobic gram-negative bacilli.

          7. Before 72h of admin agents, drug treatment which used for Systemic antibacterial
             activity against gram-negative bacteria,is less than 48 hours. If it was more than
             48h, there must be evidence for clinic failure, eg. continue fever.WBC and neutrophils
             irregular, or respiratory secretions/blood bacterial culture are positive.

          8. Informed consent granted.

        Exclusion Criteria:

          1. Pneumonia infected within 48h admission.

          2. Before 72h of admin agents, drug treatment for Systemic antibacterial activity is more
             than 48 hours, unless clinical treatment failure .

          3. Patients known or suspected by the single infection of aerobic Gram-positive cocci.

          4. Patients known to have single or mixed infections by Stenotrophomonas narrow food
             Aeromonas or Burkholderia.

          5. Patients with impaired consciousness.

          6. Patients with primary pulmonary fibrosis, cystic fibrosis, lung cinerea pneumonia,
             active tuberculosis, Bronchial obstruction, history of obstructive pneumonia (mild to
             severe COPD were admission), primary lung cancer, other tumor metastasis to the lungs,
             bronchiectasis, lung abscess, empyema, non-infectious interstitial lung disease,
             pulmonary edema, atelectasis, pulmonary embolism, pulmonary eosinophil infiltration,
             pulmonary vasculitis, pleural effusion as the primary foci, aspiration pneumonia,
             fungal pneumonia and atypical pathogens pneumonia.

          7. Patients have other bacterial infection lesions and require other antimicrobial drug
             therapy that may hinder the efficacy of the study drug evaluation.

          8. Glucocorticoids（eg ,prednisone 20mg/d, treatment≥2 week） and immunosuppressant were
             used，or known HIV positive and immunocompromised.

          9. Patients have immediate evidence of life-threatening diseases, including, but not
             limited to, acute congestive heart failure, acute coronary syndrome, or unstable
             arrhythmia.

         10. Patients with sustainable shock after making adequate fluid resuscitation (systolic
             blood pressure &gt;90mmHg) for more than 2h and having evidence of hypoperfusion or need
             sympathomimetic drugs to keep steady blood pressure.

         11. Patients with severe neutropenia syndrome (neutrophils&lt;500 cells/mm3) or expected to
             suffer severe reduction in neutrophil within 14days, or had taken G-GSF before 48h of
             study.

         12. Any patients with end-stage disease.

         13. Patients have medical record with multiple polymyxin anaphylactoid reactions.(
             urticaria, angioedema, anaphylaxis, rash, scaling, etc.)

         14. Patients have Child Pugh C chronic liver disease, or liver function is abnormal.( AST
             or AST/ALT were greater than 5 times the upper limit of normal, total bilirubin
             greater than 2 times the upper limit of normal)

         15. Patients in need of major surgery

         16. Patients with moderate or severe renal impairment (CrCL&gt;50ml/min)

         17. Patients have taken part in clinical trials of Colistimethate sodium。

         18. Patients have taken part in other drug and instrument clinical trials.

         19. Pregnant , breastfeeding and keep breastfeeding

         20. Patients involving in planning or operation of study

         21. Patients have poor compliance with study-specific procedures and related restrictions.

         22. disease which may be harmful to patients or quality of data

         23. History of epilepsy or myasthenia gravis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wu Ju Fang</last_name>
    <phone>13816357099</phone>
    <email>Wujf53@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital ,Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Seond Hospital of Jilin University</name>
      <address>
        <city>Jilin</city>
        <zip>13004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital ,Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai Tenth people's Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2013</study_first_submitted>
  <study_first_submitted_qc>September 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2013</study_first_posted>
  <last_update_submitted>September 9, 2013</last_update_submitted>
  <last_update_submitted_qc>September 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colistin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

